![Quiver Logo](/static/img/logo-icon.png)
![UNCY logo](https://quiver-logos.s3.us-east-2.amazonaws.com/uncy.png)
Unicycive Therapeutics, Inc. Common Stock
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view UNCY Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of UNCY by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by UNCY's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to UNCY
Recent picks made for UNCY stock on CNBC
ETFs with the largest estimated holdings in UNCY
Flights by private jets registered to UNCY
![Quiver Logo](/static/img/logo-icon.png)